Protein News and Research

RSS

Proteins are complex molecules that are made up of amino acids. They can be found in every cell in the body, and carry out vital processes that keep human beings alive. Mutations in proteins can lead to a multitude of diseases, the most common being cancer.

Bone cell factor can lull prostate tumor cells to sleep

Prostate tumor cells can be lulled to sleep by a factor released by bone cells, according to a study published online this week in the Journal of Experimental Medicine. Disease recurs in up to half of prostate cancer patients after treatment, often as a result of metastases that spread to distant organs.

29 Nov 2011

Abbott, GSK expand collaboration to develop additional companion diagnostic test

Abbott announced today that it will expand its existing agreement with GlaxoSmithKline Biologicals S.A. to include the development of an additional companion diagnostic test in support of GSK's cancer immunotherapy research program.

29 Nov 2011

DFG approves establishment of new research training groups

To further enhance the promotion of early-career researchers in Germany, the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) has approved the establishment of 16 new Research Training Groups. This decision was made by the DFG's relevant Grants Committee in Bonn.

29 Nov 2011

Enrollment complete in SUSTAIN Phase 2b clinical trial for atherosclerotic CVD

Resverlogix Corp. today announced that SUSTAIN, a Phase 2b clinical trial comprised of 176 subjects, is fully enrolled.

28 Nov 2011

Inspiration commences enrollment in second OBI-1 Accur8 clinical trial program for congenital hemophilia A

Inspiration Biopharmaceuticals, Inc. today announced the initiation of patient enrollment in the second of two pivotal studies in the Company's OBI-1 Accur8 clinical trial program.

28 Nov 2011

Bayer, Regeneron commence EYLEA Phase 3 clinical trial for wet AMD in China

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that they have initiated a Phase 3 clinical trial evaluating the efficacy and safety of EYLEA (aflibercept) Injection in the neovascular form of age-related macular degeneration (wet AMD) in China.

28 Nov 2011

Micromet commences blinatumomab phase 2 trial for r/r B-precursor acute lymphoblastic leukemia

Micromet, Inc. today announced that it has initiated a phase 2 trial of its lead product candidate blinatumomab (MT103) in adult patients with relapsed or refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is the first of a new class of agents called BiTE® antibodies, designed to harness the body's T cells to kill cancer cells.

28 Nov 2011

New protein involved in defense mechanism against cancer

Researchers of the Swedish medical university Karolinska Institutet and the University of Cologne, Germany, have identified a new protein involved in a defense mechanism against cancer.

28 Nov 2011

Inspiration initiates second OBI-1 phase III clinical trial in congenital hemophilia A with inhibitors

Ipsen today announced that its partner Inspiration Biopharmaceuticals, Inc. has initiated the treatment of the first patient in the second of two pivotal studies from the OBI-1's Accur8 clinical trial program.

28 Nov 2011

Novel proteomics based method detects inhibition of intracellular deubiquitylating enzymes

Researchers at the University of Oxford and Progenra, Inc. are pleased to announce the publication of a research article entitled "Activity-Based Chemical Proteomics Accelerates Inhibitor Development for Deubiquitylating Enzymes" that details a novel proteomics based method to detect inhibition of intracellular deubiquitylating enzymes (DUBs).

28 Nov 2011

Rare syndrome's workings could help explain how brain wiring goes awry

Potential clues to how autism miswires the brain are emerging from a study of a rare, purely genetic form of the disorders that affects fewer than 20 people worldwide. Using cutting-edge "disease-in a-dish" technology, researchers funded by the National Institutes of Health have grown patients' skin cells into neurons to discover what goes wrong in the brain in Timothy Syndrome.

28 Nov 2011

Moleac launches NurAiD II in France and Belgium

Biopharmaceutical Company Moleac has announced the launch in France and Belgium of NurAiD II. NurAiD II is a natural health supplement engineered to stimulate neuroplasticity and recovery.

25 Nov 2011

Transplantation of new neurons into damaged area of the brain could restore brain functions

Without neurons reacting to the blood leptin level, the brain does not control the feeling of hunger and fullness. This type of genetic defects results in severe obesity in humans and animals.

25 Nov 2011

Even normal salt intake can cause hypertension in people suffering from sodium dysregulation

Hypertension is an endemic condition with far-reaching consequences. For instance, high blood pressure is the main cause of heart attacks and strokes. Other organs are also damaged by the chronic condition.

25 Nov 2011

Scientists decode how Machado-Joseph disease arises

Neurodegenerative diseases represent one of the greatest challenges of our aging society. However, investigation into these diseases is made particularly difficult due to the limited availability of human brain tissue. Scientists from the Life & Brain Research Center and Neurology Clinic of Bonn University have now taken a roundabout path: They reprogrammed skin cells from patients with a hereditary movement disorder into so-called induced pluripotent stem cells (iPS cells) and obtained functional nerve cells from them.

24 Nov 2011

Ribosomes spontaneously change their form during protein production

Ribosomes, the construction sites for proteins, are far more complex than previously assumed. During the production of proteins they constantly and spontaneously change their form. This performance of eukaryotic ribosomes has now been demonstrated for the first time by scientists at Charité - Universitätsmedizin Berlin, the Max-Planck-Institut für Molekulare Genetik in Berlin, and Cornell University in New York, with the aid of special electron microscopic and biophysical methods.

24 Nov 2011

Dantrolene reduces severity of walking and balance problems linked with HD

Huntington's disease (HD) is characterized by ongoing destruction of specific neurons within the brain. It affects a person's ability to walk, talk, and think - leading to involuntary movement and loss of muscle co-ordination. New research published in BioMed Central's open access journal Molecular Neurodegeneration shows that the RyanR inhibitor Dantrolene is able to reduce the severity of walking and balance problems in a mouse model of HD.

24 Nov 2011

Carefully selected young, healthy neurons can repair brain circuitry

Neuron transplants have repaired brain circuitry and substantially normalized function in mice with a brain disorder, an advance indicating that key areas of the mammalian brain are more reparable than was widely believed.

24 Nov 2011

Randox expand range of immunoturbidimetric proteins

With the recent launch of the Haptoglobin and Ceruloplasmin assays Randox now have one of the largest ranges of immunoturbidimetric proteins on the market. All reagents are liquid ready to use for added convenience; furthermore, automated applications are available for most chemistry systems eliminating the need for specialised protein analysers.

From Randox Laboratories Ltd. 24 Nov 2011

ABCC9 gene also influences duration of sleep in humans

A collaborative European study led by LMU researchers has shown that ABCC9, a known genetic factor in heart disease and diabetes, also influences the duration of sleep in humans.

24 Nov 2011